Sequential Occurrence of Eosinophilic Gastrointestinal Disease in a Case of Waldenström’s Macroglobulinemia in Remission: An Unusual Report with Review
WM with EGID
-
Ankit Jitani
,
Mayur Babasaheb Mundhe
,
Kazi Wajid Husain
,
Hemant Menghani
,
Maharshi Desai
,
Velu Nair
Abstract
Waldenström macroglobulinemia (WM) is a rare lymphoproliferative malignancy presenting with para-proteinemia. The symptoms are attributable to both lymphoproliferation and IgM flare. Gastrointestinal manifestations are not uncommon. It is an indolent disease with good response to chemoimmunotherapy but with possible persistence of asymptomatic paraproteinemia. Resurgence of gastrointestinal symptoms in a patient of WM maintaining reasonable response warrant a thorough search for alternate pathology. Herein we describe a rare case of sequential occurrence of WM with Eosinophilic Gastrointestinal Disease posing a diagnostic and therapeutic challenge.
1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30(2):110–5.
2. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163–70.
3. McMaster ML, Kristinsson SY, Turesson I, et al. Novel Aspects Pertaining to the Relationship of Waldenström’s Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Polyclonal Gammopathy, and Hypoglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):19–22.
4. Waldenström J. Incipient myelomatosis or «essential« hyperglobulinemia with fibrinogenopenia — a new syndrome? Acta Med Scand. 1944;117(3‐4):216–47.
5. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenström’s macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18(1):214–26.
6. Vinarkar S, Arora N, Chowdhury SS, et al. MYD88 and CXCR4 Mutation Profiling in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinaemia. Indian J Hematol Blood Transfus. 2019;35(1):57–65.
7. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10.
8. Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia. Ann Oncol. 2004;15(10):1481–3.
9. Reed C, Woosley JT, Dellon ES. Clinical characteristics, treatment outcomes, and resource utilization in children and adults with eosinophilic gastroenteritis. Dig Liver Dis. 2015;47(3):197-201
2. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163–70.
3. McMaster ML, Kristinsson SY, Turesson I, et al. Novel Aspects Pertaining to the Relationship of Waldenström’s Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Polyclonal Gammopathy, and Hypoglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):19–22.
4. Waldenström J. Incipient myelomatosis or «essential« hyperglobulinemia with fibrinogenopenia — a new syndrome? Acta Med Scand. 1944;117(3‐4):216–47.
5. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenström’s macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18(1):214–26.
6. Vinarkar S, Arora N, Chowdhury SS, et al. MYD88 and CXCR4 Mutation Profiling in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinaemia. Indian J Hematol Blood Transfus. 2019;35(1):57–65.
7. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10.
8. Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia. Ann Oncol. 2004;15(10):1481–3.
9. Reed C, Woosley JT, Dellon ES. Clinical characteristics, treatment outcomes, and resource utilization in children and adults with eosinophilic gastroenteritis. Dig Liver Dis. 2015;47(3):197-201
| Files | ||
| Issue | Vol 18 No 4 (2024) | |
| Section | Case Report(s) | |
| Keywords | ||
| Waldenström’s macroglobulinemia; Eosinophilic gastrointestinal disease (EGID); Eosinophilia | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Jitani A, Mundhe M, Husain K, Menghani H, Desai M, Nair V. Sequential Occurrence of Eosinophilic Gastrointestinal Disease in a Case of Waldenström’s Macroglobulinemia in Remission: An Unusual Report with Review. Int J Hematol Oncol Stem Cell Res. 2024;18(4):412-415.
